BCL2L1 and prostate cancer: EP activated cleaved PARP, Bax and caspase 8/3, and attenuated the expression of procaspase 8, Bcl-2, Bcl-XL without affecting procaspase 9 from the concentration of 25 μM compared to untreated control in DU 145 prostate cancer cells as shown Figure 3a, and b.